Pegylated interferon 2a and 2b in combination with ribavirin for the treatment of chronic hepatitis C in HIV infected patients

References

• AfdhalNHDieterichDTPockrosPJ2004Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled studyGastroenterology12613021115131791
   PubMed Web of Science ®Google Scholar
• AlterMJ2006Epidemiology of viral hepatitis and HIV co-infectionJ Hepatol44SupplS6S916352363
   PubMed Web of Science ®Google Scholar
• AlvarezDDieterichDTBrauN2006Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected personsJ Viral Hepat13683916970600
   PubMed Web of Science ®Google Scholar
• Bani-SadrFCarratFPolS2005aRisk factors for symptomatic mitochon-drial toxicity in HIV/hepatitis C virus-coinfected patients during interferon plus ribavirin-based therapyJ Acquir Immune Defic Syndr40475216123681
   PubMed Web of Science ®Google Scholar
• Bani-SadrFCarratFRosenthalE2005bSpontaneous hepatic decompensation in patients coinfected with HIV and hepatitis C during interferon-ribavirin combination treatmentClin Infect Dis411806916288408
   PubMed Web of Science ®Google Scholar
• Bani-SadrFDenoeudLMorandP2007aEarly virologic failure in HIV-coinfected hepatitis C patients treated with the peginterferon-ribavirin combination: does abacavir play a role?J Acquir Immune Defic Syndr45123517460476
   PubMed Web of Science ®Google Scholar
• Bani-SadrFGoderelIPenalbaC2007bRisk factors for anaemia in human immunodeficiency virus/hepatitis C virus-coinfected patients treated with interferon plus ribavirinJ Viral Hepat146394417697016
   PubMed Web of Science ®Google Scholar
• Bani-SadrFLapidusNBedossaP2008aProgression of fibrosis in HIV and hepatitis C virus-coinfected patients treated with interferon plus riba-virin-based therapy: analysis of risk factorsClin Infect Dis467687418248298
   PubMed Web of Science ®Google Scholar
• Bani-SadrFLapidusNMelchiorJC2008bSevere weight loss in HIV/HCV-coinfected patients treated with interferon plus ribavirin: incidence and risk factorsJ Viral Hepat152556018307589
   PubMed Web of Science ®Google Scholar
• BarreiroPSimarroNNuñezM2006Sustained virological response following HCV therapy is associated with regression of liver fibrosis in HCV/HIV-co-infected patients [abstract 859]Presented at 13th Conference on Retroviruses and Opportunistic InfectionsDenver, Colorado
   Google Scholar
• BarthHLiangTJBaumertTF2004Hepatitis C virus entry: molecular biology and clinical implicationsHepatology445273516941688
   PubMed Web of Science ®Google Scholar
• BekiszJSchmeisserHHernandezJ2004Human interferons alpha, beta and omegaGrowth Factors222435115621727
   PubMed Web of Science ®Google Scholar
• BenhamouYBochetMDi MartinoV1999Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patientsHepatology301054810498659
   PubMed Web of Science ®Google Scholar
• BergTvon WagnerMNasserS2006Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginter-feron-alfa-2a plus ribavirinGastroenterology13010869716618403
   PubMed Web of Science ®Google Scholar
• BicaIMcGovernBDharR2001Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infectionClin Infect Dis32492711170959
   PubMed Web of Science ®Google Scholar
• CarratFBani-SadrFPolS2004Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trialJAMA29228394815598915
   PubMed Web of Science ®Google Scholar
• ChungRTAndersenJVolberdingP2004Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-confected personsN Engl J Med351451915282352
   PubMed Web of Science ®Google Scholar
• DaarESLynnHDonfieldS2001Relation between HIV-1 and hepatitis C viral load in patients with hemophiliaJ Acquir Immune Defic Syndr264667211391167
   PubMed Web of Science ®Google Scholar
• DalgardOMangiaA2006Short-term therapy for patients with hepatitis C virus genotype 2 or 3 infectionDrugs6618071517040112
   PubMed Web of Science ®Google Scholar
• de VeerMJHolkoMFrevelM2001Functional classification of interferon-stimulated genes identified using microarraysJ Leukocyte Biol699122011404376
   PubMed Web of Science ®Google Scholar
• FeldJJHoofnagleJH2005Mechanism of action of interferon and ribavirin in treatment of hepatitis CNature4369677216107837
   PubMed Web of Science ®Google Scholar
• FriedMWShiffmanMLReddyR2002Peginterferon alfa-2a plus riba-virin for chronic hepatitis C virus infectionN Engl J Med3479758212324553
   PubMed Web of Science ®Google Scholar
• GaleMJr2003Effector genes of interferon action against hepatitis C virusHepatology37975812717377
   PubMed Web of Science ®Google Scholar
• GrahamCSBadenLRYuE2001Influence of human immunode-ficiency virus infection on the course of hepatitis C virus infection: a meta-analysisClin Infect Dis33562911462196
   PubMed Web of Science ®Google Scholar
• GreubGLedergerberBBattegayM2000Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort StudyLancet3561800511117912
   PubMed Web of Science ®Google Scholar
• JacobsonIMBrownRSJrMcConeJ2007Impact of weight-based ribavirin with peginterferon alfa-2b in African Americans with hepatitis C virus genotype 1Hepatology469829017894323
   PubMed Web of Science ®Google Scholar
• JanssenHLBrouwerJTvan der MastRC1994Suicide associated with alfa-interferon therapy for chronic viral hepatitisJ Hepatol2124137989716
   PubMed Web of Science ®Google Scholar
• Labarga 2007.
   Google Scholar
• LafeuilladeAHittingerGChadapaudS2001Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfectionLancet357280111214134
   PubMed Web of Science ®Google Scholar
• LagunoMMurillasJBlancoJL2004Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patientsAIDS18F27F3615316335
   PubMed Web of Science ®Google Scholar
• LamarreDAndersonPCBaileyM2003An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virusNature426186914578911
   PubMed Web of Science ®Google Scholar
• LauDTKleinerDEGhanyMG199810-Year follow-up after interferon-alpha therapy for chronic hepatitis CHepatology281121279755252
   PubMed Web of Science ®Google Scholar
• LesburgCACableMBFerrariE1999Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active siteNat Struct Biol69374310504728
   PubMedGoogle Scholar
• McGovernBBicaI2002Risk of HAART therapy in hepatitis CHepatology3573011870393
   PubMed Web of Science ®Google Scholar
• McGovernB2004HAART and hepatic safetyJ Int Assoc Physicians AIDS Care3SupplS23S42
   Google Scholar
• McGovernBH2007Hepatitis C in the HIV-infected patientJ Acquir Immune Defic Syndr45Suppl 2S475617704692
   PubMed Web of Science ®Google Scholar
• McHutchisonJGGordonSCSchiffER1998Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis CN Engl J Med3391485929819446
   PubMed Web of Science ®Google Scholar
• MannsMPMcHutchisonJGGordonSC2001Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trialLancet3589586511583749
   PubMed Web of Science ®Google Scholar
• MaussSValentiWDePamphilisJ2004Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapyAIDS18F212515316334
   PubMed Web of Science ®Google Scholar
• MoradpourDBlumHE2004A primer on the molecular virology of hepatitis CLiver Int245192515566499
   PubMed Web of Science ®Google Scholar
• NunezMMarinoAMirallesC2007bBaseline hepatitis C virus RNA and response at week 4 are the best predictors of relapse after treatment with pegylated interferon plus ribavirin in HIV/hepatitis C virus-coinfected patientsJ Acquir Immune Defic Syndr454394417468669
   PubMed Web of Science ®Google Scholar
• NunezMMirallesCBerdunMA2007aRole of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trialAIDS Res Hum Retroviruses239728217725413
   PubMed Web of Science ®Google Scholar
• PayanCPivertAMorandP2007Rapid and early virological response to chronic hepatitis C treatment with IFN alpha-2b or PEG-IFN alpha-2b plus ribavirin in HIV/HCV co-infected patientsGut561111617363475
   PubMed Web of Science ®Google Scholar
• PolSNalpasBBourliereM2000Combination of ribavirin and interferon-alfa surpasses high doses of interferon-alfa alone in patients with genotype-1b-related chronic hepatitis CHepatology3113384410827161
   PubMed Web of Science ®Google Scholar
• PoynardTLeroyVCohardM1996Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and durationHepatology24778898855176
   PubMed Web of Science ®Google Scholar
• PoynardTMcHutchisonJMannsM2002Impact of pegylated interferon-alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis CGastroenterology12213031311984517
   PubMed Web of Science ®Google Scholar
• PuotiCMagriniAStatiT1997Clinical, histological, and virological features of hepatitis C virus carriers with persistently normal or abnormal alanine transaminase levelsHepatology26139389397976
   PubMed Web of Science ®Google Scholar
• RauchARickenbachMWeberR2005Unsafe sex and increased incidence of hepatitis C virus infection among HIV-infected men who have sex with men: the Swiss HIV Cohort StudyClin Infect Dis4139540216007539
   PubMed Web of Science ®Google Scholar
• ReVL3rdKostmanJRGrossR2007Incidence and risk factors for weight loss during dual HIV/hepatitis C virus therapyJ Acquir Immune Defic Syndr443445017179767
   PubMed Web of Science ®Google Scholar
• SchaeferMSchwaigerMGarkischAS2005Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis CJ Hepatol42793815885349
   PubMed Web of Science ®Google Scholar
• SenGC2001Viruses and interferonsAnnu Rev Microbiol552558111544356
   PubMed Web of Science ®Google Scholar
• ShermanKERousterSDChungRT2002Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US Adult AIDS Clinical Trials GroupClin Infect Dis34831711833007
   PubMed Web of Science ®Google Scholar
• ShuhartMC2007Hepatitis C and HIV coinfectionCurr Hepatitis Rep64653
   Google Scholar
• SorianoVMirallesCBerdunMA2007aPremature treatment discontinuation in HIV/HCV-coinfected patients receiving pegylated interferon plus weight-based ribavirinAntivir Ther124697617668555
   PubMed Web of Science ®Google Scholar
• SorianoVPuotiMSulkowskiM2007bCare of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV international panelAIDS2110738917502718
   PubMed Web of Science ®Google Scholar
• SulkowskiMS2008Viral hepatitis and HIV coinfectionJ Hepatol483536718155314
   PubMed Web of Science ®Google Scholar
• SulkowskiMSDieterichDTBiniEJ2005Epoetin alfa once weekly improves anemia in HIV/hepatitis C virus-coinfected patients treated with interferon/ribavirin: a randomized controlled trialJ Acquir Immune Defic Syndr39504616010180
   PubMed Web of Science ®Google Scholar
• TaylorLSchwartzapfelBAllenS2003Extending treatment for HCV infection to HIV-HCV coinfected individuals with psychiatric illness and drug dependenceClin Infect Dis361501212766851
   PubMed Web of Science ®Google Scholar
• ThomasDL2002Hepatitis C and human immunodeficiency virus infectionHepatology36Suppl 1S201S912407595
   PubMed Web of Science ®Google Scholar
• TilgH1997New insights into the mechanisms of interferon: an immunoregulatory and anti-inflammatory cytokineGastroenterology1121017219041265
   PubMed Web of Science ®Google Scholar
• TorrianiFJRodriguez-TorresMRockstrohJK2004Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patientsN Engl J Med3514385015282351
   PubMed Web of Science ®Google Scholar
• VispoEBPMaidaIPinedaJ2007Abacavir-containing HAART reduces the chances for sustained virologic response to pegylated-interferon plus ribavirin in HIV-infected patients with chronic hepatitis C [abstract]Third International Workshop on HIV and Hepatitis Co-infection, Abstract 46.
   Google Scholar
• WillsRJ1990Clinical Pharmacology of interferonsClin Pharmacokin193909
   PubMed Web of Science ®Google Scholar